



Identification of First-in-Class Selective ARID1B Degraders

Targeted Protein Degradation Summit


Steven Bellon, PhD (sbellon@foghornntx.com)

Chief Scientific Officer

October 29, 2025

Chromatin Regulatory System Orchestrates Gene Expression: Multiple Opportunities for Targets and Therapeutics


Chromatin Regulatory System genes are **implicated** across a **wide range of cancers**



Leveraging **synthetic lethality** and **lineage dependencies**


Foghorn is Focused on Some of the Most Relevant Genes in Cancer

Most Frequently Mutated Genes in Human Cancer




Selective ARID1B Targeting Unlocks Synthetic Lethal Strategy for the Treatment of ARID1A Mutant Cancers

Synthetic Lethal Relationship Between ARID1A and ARID1B



ARID1B Knockout Inhibits Cell Growth in ARID1A Mutant Cancer Cells




ARID1B: Drugging A Previously Undruggable Target

Drug Targeting Considerations

- Large and highly unstructured protein ~ 240 kDa
- No known enzymatic function
- Member of large, multi-subunit complex
- High sequence homology (~60%) to ARID1A


Approach

- Discover binders to ARID1B
- Use binders to develop bifunctional degraders




Foghorn Platform Yields Several Selective ARID1B Binder Series

SERIES A





SERIES B



Structure-Based Optimization Drives Improved ARID1B Binding Affinity From 100 μM to Less Than 200 nM

Screening Hit



ARID1B K_d : **100 μM**



1.4 Å co-xtal
structure

Early Optimization



ARID1B K_d : **15 μM**



2.0 Å soak
structure



Sub- μM Affinity

ARID1B K_d : **0.5 μM**



1.9 Å co-xtal
structure

ARID1B K_d : **0.2 μM**






1.7 Å soak
structure




Solubility, Media Stability, and Selectivity among other optimized parameters

Maximum Optionality Achieved Through Progression of Both Cereblon and VHL Based Degraders in Parallel

CEREBLON




VHL




Lead ARID1B Degradar Demonstrates Robust Degradation Across Multiple Cell Lines

IMMUNOBLOT




24 hours

HiBiT - ENDPOINT




24 hours

HiBiT - KINETICS




ARID1B Degradation is On-Mechanism Via Ubiquitin-Proteasome System

VHL-Inactive Degradar Does Not Affect ARID1B Levels




● Active Degradar ● Inactive Degradar

Cell Viability







Inhibitors of the UPS Pathway Rescue Degradation




● ARID1B degrader
● + 750 nM MG132 (Proteasome inhibitor)
● + 250 nM Bortezomib (Velcade, Proteasome inhibitor)
● + 750 nM MLN4924 (Neddylaton inhibitor)
● + 750 nM TAK-243 (Ub activating enzyme inhibitor)



ARID1B Degradar Exhibits High Target Selectivity




Selective ARID1B Degradation Demonstrated by Global Proteomics




Biochemical Measurements of ARID1B Residence Time Correlate with Cellular Potency of Degraders Within a Series


DC₅₀ vs Off Rate




D_{max} vs Off Rate



Native Mass Spectrometry Demonstrates Ternary Complex Formation





nMS allows for monitoring of binary and ternary complex formation





Ternary Complex Formation Confirmed in Biochemical and Cellular Proximity Assays


TR-FRET




NanoBRET




Biochemical Cooperativity Assays Provide Quantitative Understanding of Ternary Complex Formation



TR-FRET




SPR




Ternary K_D : 15 nM

VBC Binary K_D : 115 nM

First Ternary Complex X-ray Structure Reveals Unexpected Degradator Geometry Paving Way to Improved Degradator Molecules



Determined to 2.1 Å resolution




Selective ARID1B Degradation has Demonstrated Effects on Downstream Target Genes - Progressing Towards Proof of Concept


3 Day ARID1B shRNA Treatment

HCT-116 ARID1A^{mut} Cells


ARID1B Gene Expression



Down Gene A Expression




Up Gene B Expression




ARID1B Degradation Treatment

Down Gene A Expression



Up Gene B Expression



Putative target genes identified from literature and confirmed via internal shRNA efforts



Acknowledgements



Thank you!